COVID-19: Solnatide approved for compassionate use
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1379 entries already.
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
Following the completion of Danahers 19.5bn take-over of GE Healthcare Life Sciences, GEs CDMO arm is renamed Cytiva.
Low intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients
The European Medicines Agency EMA has backed eight medicines for approval at its virtual March 2020 meeting.
Scandinavian researchers have created a unified, open-source model providing a genome-wide portrait of human disease metabolism.
Paris-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test.
AC Immune SA has received a milestone payment of CHF10m from Eli Lilly and Company.
Scientists have discussed a link between Covid-19 and sepsis at a virtual symposium at Charité Berlin that might help reduce the burden of end-stage disease.
Evonik Industries has established a new animal-free and fermentation-based industrial-scale recombinant collagen production platform.
